Co-Diagnostics, Inc. (CODX)

NASDAQ: CODX · IEX Real-Time Price · USD
4.91
-0.12 (-2.39%)
May 18, 2022 4:00 PM EDT - Market closed
Market Cap166.88M
Revenue (ttm)100.56M
Net Income (ttm)40.47M
Shares Out33.99M
EPS (ttm)1.23
PE Ratio3.99
Forward PE6.14
Dividendn/a
Ex-Dividend Daten/a
Volume211,356
Open5.01
Previous Close5.03
Day's Range4.88 - 5.09
52-Week Range3.66 - 11.82
Beta-1.54
AnalystsBuy
Price Target19.72 (+301.6%)
Earnings DateMay 12, 2022

About CODX

Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, tuberculosis, hepatitis B and C, human papilloma virus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; and molecular tools for ...

IndustryHealth Care Equipment & Supplies
IPO DateJul 12, 2017
CEODwight Egan
Employees101
Stock ExchangeNASDAQ
Ticker SymbolCODX
Full Company Profile

Financial Performance

In 2021, Co-Diagnostics's revenue was $97.89 million, an increase of 31.30% compared to the previous year's $74.55 million. Earnings were $36.66 million, a decrease of -13.70%.

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for CODX stock is "Buy." The 12-month stock price forecast is 19.72, which is an increase of 301.63% from the latest price.

Price Target
$19.72
(301.63% upside)
Analyst Consensus: Buy
Stock Forecasts

News

CoDiagnostics, Inc. (CODX) Q1 Earnings and Revenues Beat Estimates

CoDiagnostics, Inc. (CODX) delivered earnings and revenue surprises of 44.44% and 6.82%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

6 days ago - Zacks Investment Research

Co-Diagnostics Reports Solid First Quarter 2022 Financial Results

Strong results highlighted by record first quarter revenue of $22.7 million and diluted EPS of $0.34 SALT LAKE CITY , May 12, 2022 /PRNewswire/ --  Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagn...

6 days ago - PRNewsWire

Co-Diagnostics, Inc. to Host Booth at Medical Fair Brasil 2022 in São Paulo on May 3-6

SALT LAKE CITY , May 3, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx,"), a molecular diagnostics company with a unique, patented platform for the development of mole...

2 weeks ago - PRNewsWire

CO-DIAGNOSTICS, INC. ANNOUNCES FIRST QUARTER 2022 EARNINGS RELEASE DATE AND WEBCAST

SALT LAKE CITY , April 28, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, a...

2 weeks ago - PRNewsWire

Why the Earnings Surprise Streak Could Continue for CoDiagnostics, Inc. (CODX)

CoDiagnostics, Inc. (CODX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

3 weeks ago - Zacks Investment Research

Co-Diagnostics, Inc. to Host Booth at ECCMID 2022 in Lisbon, Portugal on April 23-26

SALT LAKE CITY , April 22, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx,"), a molecular diagnostics company with a unique, patented platform for the development of m...

3 weeks ago - PRNewsWire

Co-Diagnostics, Inc. JV CoSara Receives Clearance from Indian Regulators for Hepatitis C Viral Load Test

SALT LAKE CITY , April 19, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular dia...

4 weeks ago - PRNewsWire

Why Co-Diagnostics Stock Tumbled by Nearly 12% Today

The company released its 2021 earnings, and investors weren't happy with them despite profitability guidance that beat estimates.

1 month ago - The Motley Fool

CoDiagnostics, Inc. (CODX) Q4 Earnings Beat Estimates

CoDiagnostics, Inc. (CODX) delivered earnings and revenue surprises of 66.67% and 5.11%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Why Co-Diagnostics Stock Is Trading Higher After Hours

Co-Diagnostics Inc (NASDAQ: CODX) shares are trading higher in Thursday's after-hours session after the company reported financial results and issued earnings guidance. Co-Diagnostics reported full year...

1 month ago - Benzinga

Co-Diagnostics Reports Full Year 2021 Financial Results

Achieved Record Full Year Revenue of $97.9 Million; Strength in Sales Momentum Provides Foundation to Achieve Solid FY'22 SALT LAKE CITY , March 24, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CO...

1 month ago - PRNewsWire

Co-Diagnostics, Inc. to Present at MarketsandMarkets Conference on March 23-24 in London, England

SALT LAKE CITY , March 22, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular dia...

1 month ago - PRNewsWire

Co-Diagnostics, Inc. Makes Strategic Additions to Scientific Advisory Board

SALT LAKE CITY , March 17, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular dia...

2 months ago - PRNewsWire

CoDiagnostics, Inc. (CODX) Surges 13.1%: Is This an Indication of Further Gains?

CoDiagnostics, Inc. (CODX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price in...

2 months ago - Zacks Investment Research

Why Co-Diagnostics Is Soaring Today

The diagnostics and research outfit gave investors a dose of good news today.

2 months ago - The Motley Fool

Why Co-Diagnostics Shares Are Trading Higher Today

Co-Diagnostics Inc (NASDAQ: CODX) shares are trading higher Tuesday after the company announced its board authorized a share repurchase program, allowing Co-Diagnostics to repurchase up to $30 million o...

2 months ago - Benzinga

Co-Diagnostics, Inc. Announces Authorization of $30 Million Share Repurchase Program

SALT LAKE CITY , March 15, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular dia...

2 months ago - PRNewsWire

CO-DIAGNOSTICS, INC. ANNOUNCES FOURTH QUARTER AND FULL YEAR 2021 EARNINGS RELEASE DATE AND WEBCAST

SALT LAKE CITY , March 14, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, a...

2 months ago - PRNewsWire

Co-Diagnostics, Inc. to Sponsor and Present at Molecular Med Tri-Con 2022

SALT LAKE CITY, Feb. 17, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagn...

3 months ago - PRNewsWire

Co-Diagnostics, Inc. to Host Booth at Life Sciences Day on the Hill on February 16 at the Utah State Capital

SALT LAKE CITY, Feb. 10, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagn...

3 months ago - PRNewsWire

Co-Diagnostics, Inc. JV CoSara Receives Clearance from Indian Regulators for Hepatitis B Viral Load Test

SALT LAKE CITY, Feb. 3, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagno...

3 months ago - PRNewsWire

Co-Diagnostics, Inc. to Host Booth at Medlab Middle East 2022 in Dubai on January 24-27

SALT LAKE CITY, Jan. 21, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagn...

3 months ago - PRNewsWire

Co-Diagnostics, Inc. JV CoSara Receives Clearance from Indian Regulators for High-Risk HPV Multiplex Test

SALT LAKE CITY, Jan. 13, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagn...

4 months ago - PRNewsWire

Co-Diagnostics, Inc. to Participate in the H.C. Wainwright 2022 BioConnect Virtual Conference on January 10-13

SALT LAKE CITY, Jan. 10, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular di...

4 months ago - PRNewsWire

Has CoDiagnostics, Inc. (CODX) Outpaced Other Medical Stocks This Year?

Here is how CoDiagnostics, Inc. (CODX) and Cronos Group (CRON) have performed compared to their sector so far this year.

4 months ago - Zacks Investment Research